CAR-T细胞免疫疗法-话题@MedSci - 梅斯（MedSci）

#CAR-T细胞免疫疗法#

7篇内容 | 1522人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2200660, encodeId=2d56220066075, content=<a href='/topic/show?id=f96c266935c' target=_blank style='color:#2F92EE;'>#体重指数#</a> <a href='/topic/show?id=6dd71001e052' target=_blank style='color:#2F92EE;'>#预后#</a> <a href='/topic/show?id=c92340e325' target=_blank style='color:#2F92EE;'>#CAR-T细胞免疫疗法#</a> <a href='/topic/show?id=c717425931e' target=_blank style='color:#2F92EE;'>#复发难治性多发性骨髓瘤#</a>, objectTitle=Cytotherapy：CAR-T细胞免疫疗法治疗复发难治性多发性骨髓瘤患者的体重指数和预后的复杂关联, objectType=article, longId=823264, objectId=36b382326436, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221120/1669014235000_4754896.webp, objectUrl=/article/show_article.do?id=36b382326436, replyNumber=0, likeNumber=159, createdTime=2024-04-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=36b382326436, moduleTitle=Cytotherapy：CAR-T细胞免疫疗法治疗复发难治性多发性骨髓瘤患者的体重指数和预后的复杂关联, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=36b382326436)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1629100, encodeId=ccb7162910013, content=<a href='/topic/show?id=c92340e325' target=_blank style='color:#2F92EE;'>#CAR-T细胞免疫疗法#</a>, objectTitle=北京发布《CAR-T细胞免疫疗法临床研究伦理审查指南》, objectType=article, longId=205468, objectId=b398205468c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b398205468c7, replyNumber=0, likeNumber=86, createdTime=2021-01-09, rootId=0, userName=andy2094, userId=bdd121300695, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b398205468c7, moduleTitle=北京发布《CAR-T细胞免疫疗法临床研究伦理审查指南》, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b398205468c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1629099, encodeId=ac671629099ca, content=<a href='/topic/show?id=c92340e325' target=_blank style='color:#2F92EE;'>#CAR-T细胞免疫疗法#</a>, objectTitle=CAR-T细胞免疫疗法临床研究与伦理审查实践, objectType=article, longId=202609, objectId=56f8202609e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56f8202609e1, replyNumber=0, likeNumber=109, createdTime=2020-10-31, rootId=0, userName=andy2094, userId=bdd121300695, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56f8202609e1, moduleTitle=CAR-T细胞免疫疗法临床研究与伦理审查实践, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=56f8202609e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1629098, encodeId=52ba162909814, content=<a href='/topic/show?id=c92340e325' target=_blank style='color:#2F92EE;'>#CAR-T细胞免疫疗法#</a>, objectTitle=Blood重磅｜CAR-NK再度出世，竟比CAR-T细胞免疫疗法更有效？, objectType=article, longId=198778, objectId=f56d198e7883, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f56d198e7883, replyNumber=0, likeNumber=104, createdTime=2020-08-07, rootId=0, userName=andy2094, userId=bdd121300695, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f56d198e7883, moduleTitle=Blood重磅｜CAR-NK再度出世，竟比CAR-T细胞免疫疗法更有效？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f56d198e7883)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1629097, encodeId=3833162909e3e, content=<a href='/topic/show?id=c92340e325' target=_blank style='color:#2F92EE;'>#CAR-T细胞免疫疗法#</a>, objectTitle=59岁患者接受CAR-T细胞免疫疗法后超过3年无癌症标志物, objectType=article, longId=192035, objectId=9c5119203548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c5119203548, replyNumber=0, likeNumber=105, createdTime=2020-04-13, rootId=0, userName=andy2094, userId=bdd121300695, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c5119203548, moduleTitle=59岁患者接受CAR-T细胞免疫疗法后超过3年无癌症标志物, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9c5119203548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1629096, encodeId=7adb162909688, content=<a href='/topic/show?id=c92340e325' target=_blank style='color:#2F92EE;'>#CAR-T细胞免疫疗法#</a>, objectTitle=CAR-T细胞免疫疗法（idecabtagene vicleucel）治疗多发性骨髓瘤, objectType=article, longId=191240, objectId=fac619124043, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fac619124043, replyNumber=0, likeNumber=107, createdTime=2020-04-03, rootId=0, userName=andy2094, userId=bdd121300695, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fac619124043, moduleTitle=CAR-T细胞免疫疗法（idecabtagene vicleucel）治疗多发性骨髓瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fac619124043)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1629095, encodeId=7e5116290958e, content=<a href='/topic/show?id=c92340e325' target=_blank style='color:#2F92EE;'>#CAR-T细胞免疫疗法#</a>, objectTitle=Blood：CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解, objectType=article, longId=173300, objectId=ce3d1e330034, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce3d1e330034, replyNumber=0, likeNumber=76, createdTime=2019-06-28, rootId=0, userName=andy2094, userId=bdd121300695, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce3d1e330034, moduleTitle=Blood：CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ce3d1e330034)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1629094, encodeId=f1f61629094ac, content=<a href='/topic/show?id=c92340e325' target=_blank style='color:#2F92EE;'>#CAR-T细胞免疫疗法#</a>, objectTitle=Science：CAR-T细胞免疫疗法重要突破, objectType=article, longId=81293, objectId=8c95812931c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c95812931c, replyNumber=0, likeNumber=87, createdTime=2016-10-30, rootId=0, userName=andy2094, userId=bdd121300695, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c95812931c, moduleTitle=Science：CAR-T细胞免疫疗法重要突破, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8c95812931c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CAR-T细胞免疫疗法

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#体重指数# #预后# #CAR-T细胞免疫疗法# #复发难治性多发性骨髓瘤#

Cytotherapy：CAR-T细胞免疫疗法治疗复发难治性多发性骨髓瘤患者的体重指数和预后的复杂关联

2024-04-27发表于威斯康星

andy2094 (审核中...)

前往app查看评论内容

#CAR-T细胞免疫疗法#

北京发布《CAR-T细胞免疫疗法临床研究伦理审查指南》

2021-01-09

andy2094 (审核中...)

前往app查看评论内容

#CAR-T细胞免疫疗法#

CAR-T细胞免疫疗法临床研究与伦理审查实践

2020-10-31

andy2094 (审核中...)

前往app查看评论内容

#CAR-T细胞免疫疗法#

Blood重磅｜CAR-NK再度出世，竟比CAR-T细胞免疫疗法更有效？

2020-08-07

andy2094 (审核中...)

前往app查看评论内容

#CAR-T细胞免疫疗法#

59岁患者接受CAR-T细胞免疫疗法后超过3年无癌症标志物

2020-04-13

andy2094 (审核中...)

前往app查看评论内容

#CAR-T细胞免疫疗法#

CAR-T细胞免疫疗法（idecabtagene vicleucel）治疗多发性骨髓瘤

2020-04-03

andy2094 (审核中...)

前往app查看评论内容

#CAR-T细胞免疫疗法#

Blood：CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解

2019-06-28

andy2094 (审核中...)

前往app查看评论内容

#CAR-T细胞免疫疗法#

Science：CAR-T细胞免疫疗法重要突破

2016-10-30

科室
- - 订阅+
  - 更多科室
工具
服务